HIV infection – a new disease of internal medicine

Czech version

Authors: Svatava Snopková
Authors‘ workplace: Klinika infekčních chorob LF MU a FN Brno, pracoviště Bohunice
Published in: Vnitř Lék 2017; 63(7-8): 502-506
Category: Reviews

Overview

Modern antiretroviral treatment belongs to the greatest success of current medicine. HIV infection has gone from a death sentence to a manageable chronic disease which develops several decades. Thanks to treatment advances, people with HIV can and do live long and full lives. In the last two decades, the incidence AIDS defining illnesses have been dramatically reduced especially opportunistic infections and malignancies, whereas the role of non-infection comorbidities has risen than age-matched HIV uninfected adults. These comorbidities include cardiovascular diseases, venous and arterial thrombosis, metabolic disorders, chronic liver and renal diseases, nervous system disorders, osteoporosis and some cancers. This relatively large group of diseases is known as non-AIDS defining or indicating diseases and these diseases are associated in HIV uninfected general population with older age and ageing Most HIV positive individuals on antiretrovirals present an abnormal level of immune activation, inflammation and hypercoagulable condition. These hallmarks are typically seen in older HIV uninfected general population and are associated with aging and the immunosenescent phenotype. The explanation for this phenomenon is unclear. There are multiple factors, which may apply pathophysiologically, including the residual immune dysregulation syndrome and antiretrovirals alone. It is clear that changes in the nature of chronic HIV infection put it in internal medicine. Cardiology, internal medicine, geriatric and oncology syndromes are dominating manifestations in HIV positive patients on antiretrovirals. Care management for HIV infected individuals will need to draw on a wide range of medical disciplines in diagnosis and treatment. Clarification of these phenomena would be beneficial for the treatment of these non-infectious diseases in HIV positive and as well in HIV negative general population.

Key words:
antiretroviral therapy – HIV infection – immune dysregulation – immunosenescence – non-AIDS disease

Sources

1. Hoffmann C. Overview of Antiretroviral Agents. In: Hoffmann C, Rockstroh JK (eds). HIV 2012/2013. Medizin Fokus Verlag: Hamburg 2012: 60–110. IBSN 978–3–941727–11–3. Dostupné z WWW: <https://hivbook.files.wordpress.com/2011/10/hivbook-2012.pdf>.

2. Snopková S, Husa P. Současné možnosti antiretrovirové léčby. Remedia 2015; 25(5): 1–6.

3. Cohen MS, Chen YQ, McCauley M et al. Prevention of HIV-1 infection with early antiviral therapy. N Engl J Med 2011; 365(6): 493–505. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1105243>.

4. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. [DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC)]. Dostupné z WWW: <https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/>.

5. Günthard HF, Aberg JA, Eron JJ et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 2014; 312(4): 410–425. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2014.8722>.

6. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. World Health Organization Publication 2013. Dostupné z WWW: <http://www.who.int/hiv/pub/guidelines/arv2013/>.

7. Van Sighem A, Gras L, Reiss P et al. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 2010; 24(10): 1527–1535. Dostupné z DOI: <http://dx.doi.org/10.1097/QAD.0b013e32833a3946>.

8. Nakagawa F, Lodwick RK, Smith CJ et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012; 26(3): 335–343. Dostupné z DOI: <http://dx.doi.org/10.1097/QAD.0b013e32834dcec9>.

9. Luz PM, Bruyand M, Ribeiro S et al. [IPEC/FIOCRUZ Cohort and the Aquitaine ANRS C03 Study Group]. AIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral therapy, France and Brazil, 2000–2008: hospital-based cohort studies. BMC Infect Dis 2014; 14: 278. Dostupné z DOI: <http://dx.doi.org/10.1186/1471–2334–14–278>. .

10. Lundgren J. Antiviral therapy – thinking ahead: implications of the DAD and START studies. 15th European AIDS Conference and 17th International Workshop on Comorbidities and Adverse Drug Reactions in HIV. Barcelona, 2015. Dostupné z WWW: <http://www.aidsmap.com/Benefits-of-early-HIV-treatment-are-clear-but-issues-raised-by-START-and-DAD-remain-unresolved/page/3008853/>.

11. Snopková S, Matýšková M, Povolná K et al. HIV lipodystrofie. Vnitř Lék 2010; 56(12): 1217–1222.

12. Finkelstein JL, Gala P, Rochford R et al. HIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settings. J Int Soc AIDS 2015; 18: 19033. Dostupné z DOI: <http://dx.doi.org/10.7448/IAS.18.1.19033>.

13. Apostolova N, Blas-Garcia A, Esplugues J. Mitochondrial toxicity in HAART: An overview of in vitro evidence. Curr Pharm Des 2011; 17(20): 2130–2144.

14. Friis-Moller N, Sabin CA, Weber R et al. [Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group]. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349(21): 1993–2003.

15. Shen YM, Frenkel EP. Thrombosis and hypercoagulable state in HIV-infected patients. Clin Appl Thromb Hemost 2004; 10(3): 277–280.

16. Beltrán LM, Rubio-Navarro A, Amaro-Villalobos JM et al. Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus. Vasc Health Risk Manag 2015; 11: 35–48. Dostupné z DOI: <http://dx.doi.org/10.2147/VHRM.S65885>.

17. Smit M, Brinkman K, Geerlings S et al. [ATHENA observational cohort]. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis 2015; 15(7): 810–818. Dostupné z DOI: <http://dx.doi.org/10.1016/S1473–3099(15)00056–0>.

18. Wada NI, Jacobson LP, Margolick JB et al. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS 2015; 29(4): 463–471. Dostupné z DOI: <http://dx.doi.org/10.1097/QAD.0000000000000545>.

19. Grulich AE, van Leeuwen MT, Falster MO et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370(9581): 59–67.

20. Sico JJ, Chang CC, So-Armah K et al. HIV status and the risk of ischemic stroke among men. Neurology 2015; 84(19): 1933–1940. Dostupné z DOI: <http://dx.doi.org/10.1212/WNL.0000000000001560>.

21. Mocroft A, Reiss P, Gasiorowski J et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr 2010; 55(2): 262–270. Dostupné z DOI: <http://dx.doi.org/10.1097/QAI.0b013e3181e9be6b>.

22. Freiberg MS, Chang CC, Kuller LH et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173(8): 614–622. Dostupné z DOI: <http://dx.doi.org/10.1001/jamainternmed.2013.3728>.

23. Berry SA, Fleishman JA, Moore RD et al. HIV Research Network. Trends in reasons for hospitalization in a multiside United States cohort of persons living with HIV, 2001–2008. J Acquir Immune Defic Syndr 2012; 59(4): 368–375. Dostupné z DOI: <http://dx.doi.org/10.1097/QAI.0b013e318246b862>.

24. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet 2013; 382(9903): 1525–1533. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(13)61809–7>.

25. Guaraldi G, Orlando G, Zona S et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011; 53(11): 1120–1126. <http://dx.doi.org/10.1093/cid/cir627>.

26. Karim R, Mack WJ, Kono N et al. T-cell activation, both pre- and post-HAART levels, correlates with carotid artery stiffness over 6,5 years among HIV-infected women in the WIHS. J Acquir Immune Defic Syndr 2014; 67(3): 349–356. Dostupné z DOI: <http://dx.doi.org/10.1097/QAI.0000000000000311>.

27. Vigano S, Negron J, Ouyang Z et al. Prolonged antiretroviral therapy preserves HIV-1-specific CD8 T cells with stem cell-like properties. J Virol 2015; 89(15): 7829–7840. Dostupné z DOI: <http://dx.doi.org/10.1128/JVI.00789–15>.

28. Lederman MM, Funderburg NT, Sekaly RP et al. Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol 2013; 119: 51–83. Dostupné z DOI: <http://dx.doi.org/10.1016/B978–0–12–407707–2.00002–3>.

29. Serrano-Villar S, Pérez-Elías MJ, Dronda F et al. Increased risk of serious non-related events in HIV-infected subjects on antiretroviral therapy associated with a low CD4/CD8 ratio. PLoS One 2014; 9(1): e85798. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0085798>.

30. Eberhard JM, Ahmad F, Hong HS et al. Partial recovery of senescence and differentiation disturbances in CD8+ T cell effector-memory cells in HIV-1 infection after initiation of ART. Clin Exp Immunol 2016; 186(2): 227–238. Dostupné z DOI: <http://dx.doi.org/10.1111/cei.12837>.

31. Manavalan JS, Arpadi S, Tharmarajah S et al. Abnormal bone acquisition with early-life HIV infection: role of immune activation and senescent osteogenic precursors. J Bone Miner Res 2016; 31(11): 1988–1996. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.2883>.

32. Funderburg NT. Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients. Curr Opin HIV AIDS 2014; 9(1): 80–86. Dostupné z DOI: <http://dx.doi.org/10.1097/COH.0000000000000019>.

33. Schuetz A, Deleage C, Sereti I et al. Initiation of ART during early acute HIV infection preserves mucosal Th 17 function and reverses HIV-related immune activation. PLoS Pathog 2014; 10(12): e1004543. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.ppat.1004543>.

34. Hatano H, Delwart EL, Norris PJ et al. Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. Aids 2010; 24(16): 2535–2539. Dostupné z DOI: <http://dx.doi.org/10.1097/QAD.0b013e32833dba03>.

35. Hunt PW, Martin JN, Sinclair E et al. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis 2011; 203(10): 1474–1483. Dostupné z DOI: <http://dx.doi.org/10.1093/infdis/jir060>.

36. Silva EF, Charreau I, Gourmel B et al. ANRS 138 EASIER Study Group. Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy. J Infect Dis 2013; 208(6): 892–897. Dostupné z DOI: <http://dx.doi.org/10.1093/infdis/jit280>.

37. Torres RA, Lewis W. Aging and HIV/AIDS: pathogenetic role of therapeutic side effects. Lab Invest 2014; 94(2): 120–128. Dostupné z DOI: <http://dx.doi.org/10.1038/labinvest.2013.142>.

38. Smith RL, de Boer R, Brul S et al. Premature and accelerated aging: HIV and HAART? Front Genet 2013; 3: 328. Dostupné z DOI: <http://dx.doi.org/10.3389/fgene.2012.00328>.

39. Hukezalie KR, Thumati NR, Coté HC et al. In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs. PLoS One 2012; 7(11): e47505. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0047505>.

40. Leeansyah E, Cameron PU, Solomon A et al. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis 2013; 207(7): 1157–1165. Dostupné z DOI: <http://dx.doi.org/10.1093/infdis/jit006>.

41. Appay V, Sauce D. Assessing immune aging in HIV-infected patients. Virulence 2016; 8(5): 529–538. Dostupné z DOI: <http://dx.doi.org/10.1080/21505594.2016.1195536>.

42. Lefévre C, Auclair M, Boccara F et al. Premature senescence of vascular cells is induced by HIV protease inhibitors: implication of prelamin A and reversion by statin. Arterioscler Thromb Vasc Biol 2010; 30(12): 2611–2620. Dostupné z DOI: <http://dx.doi.org/10.1161/ATVBAHA.110.213603>.

43. Wang Y, Ostlund C, Choi JC et al. Blocking farnesylation of the prelamin A variant in Hutchinson-Gilford progeria syndrome alters the distribution of A-type lamins. Nucleus 2012; 3(5): 452–462. Dostupné z DOI: <http://dx.doi.org/10.4161/nucl.21675>.

44. Smit M, Brinkman K, Geerlings S et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis 2015; 15(7): 810–818. Dostupné z DOI: <http://dx.doi.org/10.1016/S1473–3099(15)00056–0>.

45. D´Ettore G, Ceccarelli G, Pavone P et al. What happens to cardiovascular system behind the undetectable level of HIV viremia? AIDS Res Ther 2016; 13: 21. Dostupné z DOI: <http://dx.doi.org/10.1186/s12981–016–0105-z>.